Ocugen, Inc. Announces Positive DSMB Recommendation for OCU4

25.04.2022 - Phase 1/2 study to assess the safety and efficacy of OCU400 modifier gene therapy candidate to treat Retinitis Pigmentosa associated with NR2E3 and RHO mutationsMALVERN, Pa., April 25, 2022 (GLOBE NEWSWIRE) - Ocugen, Inc. (NASDAQ: OCGN), a ... Seite 1

Related Keywords

Oregon , United States , Mark Pennesi , Paulh Casey Ophthalmic Genetics Division , Oregon Health Science University , Ophthalmic Genetics Division , Oregon Health , Science University , Retina Scientific Advisory ,